CYFRA 21–1 Enzyme-Linked Immunosorbent Assay

Lai, Ruay-Sheng; Hsu, Hon-Ki; Lu, Jau-Yeong; Ger, Luo‐Ping; Lai, Ning‐Sheng

doi:10.1378/chest.109.4.995

Cited by 75 publications

(14 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ROC curve analysis showed 3.4 ng/ml as the most suitable level to distinguish to differentiate between metastatic and nonmetastatic NSCLC. This cut-of level obtained was not much higher than those of previously recommended cut-off level of CYFRA21-1 for the diagnosis of lung cancer irrespective of kit studied [1][2][3]. This means that there is a possibility of distant metastasis when pathological-proven NSCLC patient has elevated (>3.4 ng/ml) serum level of CYFRA21-1.…”

Section: Cut-off Levels Of Cyfra21-1 To Differentiate Between Metastamentioning

confidence: 54%

“…CYFRA21-1 has already been evaluated as a useful tumor marker for non-small cell lung cancer (NSCLC) [1][2][3]. Many previous reports showed that elevated serum CYFRA21-1 levels were usually indicative of extensive disease [1][2][3].…”

Section: Cut-off Levels Of Cyfra21-1 To Differentiate Between Metastamentioning

confidence: 99%

“…Many previous reports showed that elevated serum CYFRA21-1 levels were usually indicative of extensive disease [1][2][3]. However, little attention has been given to the optimal serum level of CYFRA21-1 to differentiate NSCLC patients with metastasis from those without it.…”

Section: Cut-off Levels Of Cyfra21-1 To Differentiate Between Metastamentioning

confidence: 99%

See 2 more Smart Citations

Cut-off levels of CYFRA21-1 to differentiate between metastatic and non-metastatic NSCLC

et al. 2005

View full text Add to dashboard Cite

Section: Cut-off Levels Of Cyfra21-1 To Differentiate Between Metastamentioning

confidence: 54%

Section: Cut-off Levels Of Cyfra21-1 To Differentiate Between Metastamentioning

confidence: 99%

See 1 more Smart Citation

Cut-off levels of CYFRA21-1 to differentiate between metastatic and non-metastatic NSCLC

et al. 2005

View full text Add to dashboard Cite

“…Serum CYFRA 21-1 level was not influenced by sex and smoking habits [38, 39], which was found to be an independent prognostic factor of survival and tumour relapse [40]. The meta-analysis about prognostic significance of CYFRA 21-1 has been studied in several articles, which have indicated that high level expression of CYFRA 21-1 implies a poor prognosis [32, 34, 41–48].…”

Section: Discussionmentioning

confidence: 99%

Systematic review of CYFRA 21-1 as a prognostic indicator and its predictive correlation with clinicopathological features in Non-small Cell Lung Cancer: A meta-analysis

Zhang

Yang

et al. 2016

Oncotarget

View full text Add to dashboard Cite

AIMTo evaluate the value of Cytokeratin 19 fragment for its survival prognostic indicator and predictive correlation with clinicopathological features in Non-small Cell Lung Cancer.METHODSEligible studies or databases for articles were retrieved via search systematically. Pooled effect was calculated to evaluate the association between Cytokeratin 19 fragment level and long-term overall survival, as well as the tumor clinicopathological features in Non-small Cell Lung Cancer patients. A fixed-effects or random-effects model was used to calculate the Pooled risk ratios (RRs) and corresponding 95 % confidence intervals (CIs).RESULTSSix studies were up to the selection criteria. This meta-analysis indicated that Cytokeratin 19 fragment high level expression correlated with lower 2-year overall survival (RR =0.47; 95%CI: 0.28-0.79), higher Tumor Node Metastasis stage (II+III+IV) (RR =1.43; 95%CI: 1.15-1.76) in Non-small Cell Lung Cancer. The pooled RR estimates indicated that there is no statistical significance of Cytokeratin 19 fragment level expression in the advanced Non-small Cell Lung Cancer (IIIB+IV) (RR =1.43, 95% CI: 0.85-2.43).CONCLUSIONCytokeratin 19 fragment is a negative prognosis indicator and its high level expression indicates higher Tumor Node Metastasis pathological stage (II+III+IV) in Non-small Cell Lung Cancer. In advanced Non-small Cell Lung Cancer, the level of serum Cytokeratin 19 fragment appears to provide more prognostic information than it does for clinical Tumor Node Metastasis stage information. Further studies are required to confirm our results.

show abstract

“…CYFRA21-1 has already been evaluated as a useful tumor marker for NSCLC [32]. Several studies found that CYFRA21-1 of patients with lung lesions [18] was elevated in all cell types of lung cancer, which was more sensitive in advanced stages of disease, useful in monitoring the course of disease, and prognostically meaningful.…”

Section: Discussionmentioning

confidence: 99%

Decline of serum CYFRA21-1 during chemoradiotherapy of NSCLC: a probable predictive factor for tumor response

Wang

Zhang

et al. 2011

Tumor Biol.

View full text Add to dashboard Cite

We investigated the predictive value of decline in the serum levels of tumor markers on tumor response during the chemoradiotherapy (CRT) in patients with non-small cell lung cancer (NSCLC). The serum levels of cytokeratin 19 fragment antigen 21-1 (CYFRA21-1), neurone-specific enolase and carcinoembryonic antigen were measured by enzyme-linked immunosorbent assays, while the tumor responses were assessed according to the World Health Organization response criteria. The relationship between the changes of serum level of tumor markers and the radiologic response were analyzed. The effective rates (CR + PR) in CYFRA21-1 (pretreatment serum level) high and low groups were 45.8% (33/72) and 66.7% (24/36), respectively (p=0.032). Independent sample t test showed that the relationship between the response of CYFRA21-1 and the radiologic objective response are significantly different (p=0.008). The best cutoff value of the decline ratio of CYFRA21-1 was established as 18.48% by ROC curve. CYFRA 21-1 responses appeared to be reliable surrogate markers to predict chemoradiotherapy efficacy in patients with NSCLC, an average drop of 18.48% in serum CYFRA21-1 appears to provide the predictive information for the sensitivity of CRT.

show abstract

CYFRA 21–1 Enzyme-Linked Immunosorbent Assay

Cited by 75 publications

References 14 publications

Cut-off levels of CYFRA21-1 to differentiate between metastatic and non-metastatic NSCLC

Cut-off levels of CYFRA21-1 to differentiate between metastatic and non-metastatic NSCLC

Systematic review of CYFRA 21-1 as a prognostic indicator and its predictive correlation with clinicopathological features in Non-small Cell Lung Cancer: A meta-analysis

Decline of serum CYFRA21-1 during chemoradiotherapy of NSCLC: a probable predictive factor for tumor response

Contact Info

Product

Resources

About